Filenews 18 February 2021
International clinical trials of the single-dose Sputnik-light vaccine have begun in Moscow, Moscow mayor Sergey Sobyanin announced.
The new formulation, developed by the Gamalei Institute, is called upon to eliminate the basic deficiency of the classic Sputnik-V vaccine, which are the two doses administered to the vaccinated one with a difference of a few weeks from each other, Sobyanin said, adding that immunity is created one week after vaccination, reaching a maximum after four weeks.
6,000 volunteers
Sobyanin also said Sputnik-light carried out the first and second phase of clinical trials, while 6,000 volunteers, 3,000 from Russia and 3,000 from the United Arab Emirates will participate in the third phase clinical trials.
The mayor of Moscow said that the clinical trials, to be carried out in 10 polyclinics in the Russian capital, can be attended by any adult citizen for whom there are no contra-indications and who has not been vaccinated with the Sputnik-V vaccine.
COVIVAC
Registration for approval of the third Russian vaccine against the new coronavirus, Covivac, developed by the Chumakov science centre, is scheduled to take place on February 20th, according to a statement posted on a government website for the coronavirus.
The same communication states that large-scale third-phase clinical trials involving 3,000 volunteers are planned. During the first phase of clinical trials, 200 volunteers participated, in which no adverse side effects were detected.
The second phase of clinical trials began in December 2020 in St. Petersburg, Novosibirsk and Kirov, which also involved 200 volunteers. On 20 January 2021 the Russian Ministry of Health received the documents required for the registration of the Covivac vaccine.
Source: eyenews/KYPE
Source: news.in.gr
